US Stock MarketDetailed Quotes
ABOS Acumen Pharmaceuticals
- 3.220
- +0.040+1.26%
Close Apr 30 16:00 ET
- 3.310
- +0.090+2.80%
Post 18:23 ET
193.46MMarket Cap-2981P/E (TTM)
3.245High3.150Low82.94KVolume3.160Open3.180Pre Close266.18KTurnover0.26%Turnover RatioLossP/E (Static)60.08MShares11.31052wk High0.72P/B103.94MFloat Cap1.81052wk Low--Dividend TTM32.28MShs Float26.980Historical High--Div YieldTTM2.99%Amplitude1.810Historical Low3.209Avg Price1Lot Size
Acumen Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -22.50%-43.06M | 25.79%-8.31M | -40.53%-12.91M | -80.43%-11.67M | -22.61%-10.18M | -95.72%-35.15M | -207.86%-11.2M | -19.45%-9.18M | -51.69%-6.47M | -250.17%-8.3M |
| Net income from continuing operations | -22.20%-52.37M | -28.22%-16.5M | -20.98%-12.96M | -14.37%-11.61M | -23.86%-11.31M | 57.40%-42.86M | -54.10%-12.87M | -174.47%-10.71M | 83.46%-10.15M | 66.19%-9.13M |
| Operating gains losses | --1.35M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 8.88%184K | -20.41%39K | -9.09%40K | 35.90%53K | 40.54%52K | 4,125.00%169K | 1,533.33%49K | 4,300.00%44K | --39K | --37K |
| Other non cash items | --884K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | -3.01%3.87M | 643.73%6.05M | -294.25%-878K | -148.32%-1.33M | 158.54%24K | 1,237.58%3.99M | -80.01%814K | 111.06%452K | 383.76%2.76M | -103.19%-41K |
| -Change in prepaid assets | -121.71%-369K | 118.72%67K | 222.30%1.5M | -155.41%-1.03M | -163.49%-899K | 143.80%1.7M | -186.06%-358K | 61.62%-1.22M | 275.38%1.87M | 3,318.18%1.42M |
| -Change in payables and accrued expense | 71.80%4.4M | 373.90%6.01M | -239.56%-2.37M | -126.05%-249K | 173.90%1.01M | -38.95%2.56M | -65.33%1.27M | 289.29%1.7M | 950.55%956K | -201.42%-1.36M |
| -Change in other current assets | 48.91%-70K | 45.76%-32K | 35.71%19K | 51.85%-13K | 32.31%-44K | -878.57%-137K | -5,800.00%-59K | --14K | ---27K | -400.00%-65K |
| -Change in other current liabilities | 32.12%-93K | 127.03%10K | 20.59%-27K | -11.76%-38K | -18.75%-38K | ---137K | ---37K | ---34K | ---34K | ---32K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -22.50%-43.06M | 25.79%-8.31M | -40.53%-12.91M | -80.43%-11.67M | -22.61%-10.18M | -95.72%-35.15M | -207.86%-11.2M | -19.45%-9.18M | -51.69%-6.47M | -250.17%-8.3M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -538.10%-171.67M | -139.02%-48.81M | -264.53%-92M | 25.94%11.06M | -722.26%-41.93M | 137.63%39.19M | -103.98%-20.42M | 159.42%55.92M | 146,516.67%8.79M | -5.1M |
| Net PPE purchase and sale | 88.82%-18K | 60.00%-14K | 95.06%-4K | --0 | --0 | -302.50%-161K | -34.62%-35K | -912.50%-81K | -500.00%-36K | ---9K |
| Net investment purchase and sale | -536.27%-171.65M | -139.36%-48.79M | -264.28%-92M | 25.43%11.06M | -723.71%-41.93M | 137.80%39.35M | -104.16%-20.39M | 159.51%56M | --8.82M | ---5.09M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -538.10%-171.67M | -139.02%-48.81M | -264.53%-92M | 25.94%11.06M | -722.26%-41.93M | 137.63%39.19M | -103.98%-20.42M | 159.42%55.92M | 146,516.67%8.79M | ---5.1M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 3,784.13%151.75M | 596.32%29.13M | 46,778.33%122.76M | -98.05%3.91M | 41,740.00%4.18M | -100.16%-263K | ||||
| Net issuance payments of debt | --30M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net common stock issuance | 3,114.77%121.9M | -110.28%-390K | ---- | ---- | ---- | -97.75%3.79M | 126,500.00%3.79M | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | 182.61%325K | --0 | 16,150.00%325K | ---- | ---- | -93.88%115K | 638.46%96K | 0.00%2K | ---- | ---- |
| Net other financing activities | ---476K | ---- | ---- | ---- | ---- | ---- | ---- | ---265K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 3,784.13%151.75M | 596.32%29.13M | 46,778.33%122.76M | ---- | ---- | -98.05%3.91M | 41,740.00%4.18M | -100.16%-263K | ---- | ---- |
| Net cash flow | ||||||||||
| Beginning cash position | 6.50%130.1M | -39.63%95.11M | -30.45%77.25M | -28.29%78M | 6.50%130.1M | 179.06%122.16M | 16.01%157.54M | 61.41%111.07M | 162.67%108.76M | 179.06%122.16M |
| Current changes in cash | -893.32%-62.98M | -2.00%-27.99M | -61.57%17.86M | -132.61%-751K | -288.88%-52.1M | -89.87%7.94M | -101.17%-27.44M | -30.63%46.47M | -91.60%2.3M | -465.32%-13.4M |
| End cash Position | -48.41%67.12M | -48.41%67.12M | -39.63%95.11M | -30.45%77.25M | -28.29%78M | 6.50%130.1M | 6.50%130.1M | 16.01%157.54M | 61.41%111.07M | 162.67%108.76M |
| Free cash flow | -22.01%-43.09M | 25.89%-8.33M | -39.38%-12.91M | -79.43%-11.67M | -22.47%-10.18M | -96.18%-35.31M | -206.63%-11.24M | -20.37%-9.26M | -52.32%-6.5M | -250.55%-8.31M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg